AR 24

Drug Profile

AR 24

Alternative Names: AR24

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arbor Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Endocrine disorders

Most Recent Events

  • 12 Oct 2016 Preregistration for Endocrine disorders (unspecified route) (Arbor Pharmaceuticals pipeline, October 2016)
  • 25 Jul 2016 Phase-III clinical trials in Endocrine disorders (In infants, In children, In adolescents, In neonates)(unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top